DK1253918T3 - Præparater der omfatter modafinil til behandling af forstyrrelse af opmærksomhed og aktivitet ("Attention Deficit Hyperactivity Disorder" ADHD)) - Google Patents

Præparater der omfatter modafinil til behandling af forstyrrelse af opmærksomhed og aktivitet ("Attention Deficit Hyperactivity Disorder" ADHD))

Info

Publication number
DK1253918T3
DK1253918T3 DK00954081T DK00954081T DK1253918T3 DK 1253918 T3 DK1253918 T3 DK 1253918T3 DK 00954081 T DK00954081 T DK 00954081T DK 00954081 T DK00954081 T DK 00954081T DK 1253918 T3 DK1253918 T3 DK 1253918T3
Authority
DK
Denmark
Prior art keywords
attention
hyperactivity disorder
deficit hyperactivity
adhd
treatment
Prior art date
Application number
DK00954081T
Other languages
Danish (da)
English (en)
Inventor
Matthew S Miller
Thomas E Scammell
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of DK1253918T3 publication Critical patent/DK1253918T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK00954081T 1999-08-16 2000-08-16 Præparater der omfatter modafinil til behandling af forstyrrelse af opmærksomhed og aktivitet ("Attention Deficit Hyperactivity Disorder" ADHD)) DK1253918T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14961299P 1999-08-16 1999-08-16
US09/638,353 US6346548B1 (en) 1999-08-16 2000-08-15 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
PCT/US2000/022338 WO2001012170A2 (en) 1999-08-16 2000-08-16 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue

Publications (1)

Publication Number Publication Date
DK1253918T3 true DK1253918T3 (da) 2008-12-08

Family

ID=26846889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00954081T DK1253918T3 (da) 1999-08-16 2000-08-16 Præparater der omfatter modafinil til behandling af forstyrrelse af opmærksomhed og aktivitet ("Attention Deficit Hyperactivity Disorder" ADHD))

Country Status (19)

Country Link
US (3) US6346548B1 (https=)
EP (1) EP1253918B1 (https=)
JP (1) JP5542291B2 (https=)
KR (1) KR100728080B1 (https=)
CN (1) CN100450475C (https=)
AT (1) ATE410157T1 (https=)
AU (1) AU778360B2 (https=)
BR (1) BR0013555A (https=)
CA (2) CA2689735A1 (https=)
CY (1) CY1109079T1 (https=)
DE (1) DE60040487D1 (https=)
DK (1) DK1253918T3 (https=)
ES (1) ES2313902T3 (https=)
IL (2) IL147794A0 (https=)
MX (1) MXPA02001587A (https=)
NO (1) NO331307B1 (https=)
NZ (1) NZ516767A (https=)
PT (1) PT1253918E (https=)
WO (1) WO2001012170A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
ES2277937T3 (es) * 2000-07-27 2007-08-01 Teva Pharmaceutical Industries Ltd. Modafinilo puro y cristalino y su procedimiento de preparacion.
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
JP2004536819A (ja) 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6821979B2 (en) * 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
CN101606916B (zh) * 2002-09-13 2011-02-09 赛福伦公司 莫达非尼片剂及其应用
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR045423A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
US7449481B2 (en) * 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
US7314875B2 (en) * 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
EP1586560A1 (en) * 2004-04-13 2005-10-19 Cephalon, Inc. Thio-substituted arylmethanesulfinyl derivatives
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
CA2575790A1 (en) * 2004-09-24 2006-03-30 Centre For Addiction And Mental Health The use of a modafinil compound for the treatment of problem gambling
JP2009503020A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090023712A1 (en) * 2006-02-18 2009-01-22 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
MX2008013827A (es) * 2006-05-09 2008-11-10 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) * 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
US20100010092A1 (en) * 2006-12-19 2010-01-14 Arless Ltd. Use of modafinil to treat restless leg syndrome
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
US9289403B2 (en) * 2007-03-09 2016-03-22 The Board of Trustees of the University of Arizona Use of modafinil to treat spasticity
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
FR2970711B1 (fr) 2011-01-20 2016-03-04 Hopitaux Paris Assist Publique La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
KR102150417B1 (ko) * 2018-08-29 2020-09-01 경북대학교 산학협력단 복외측전시각영역 내 성상세포의 광유전학적 자극을 통한 수면 유도 동물 모델 및 이를 이용한 수면 제어제의 스크리닝 방법
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
FR2707637B1 (fr) 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen

Also Published As

Publication number Publication date
US6488164B2 (en) 2002-12-03
US6346548B1 (en) 2002-02-12
US20030069313A1 (en) 2003-04-10
JP5542291B2 (ja) 2014-07-09
HK1051006A1 (en) 2003-07-18
CY1109079T1 (el) 2014-07-02
ES2313902T3 (es) 2009-03-16
CN1635875A (zh) 2005-07-06
KR100728080B1 (ko) 2007-06-14
EP1253918B1 (en) 2008-10-08
KR20020038726A (ko) 2002-05-23
BR0013555A (pt) 2007-03-27
WO2001012170A2 (en) 2001-02-22
ATE410157T1 (de) 2008-10-15
NZ516767A (en) 2004-03-26
NO331307B1 (no) 2011-11-21
AU778360B2 (en) 2004-12-02
CA2380673C (en) 2010-03-30
NO20020772D0 (no) 2002-02-15
EP1253918A2 (en) 2002-11-06
DE60040487D1 (de) 2008-11-20
CA2380673A1 (en) 2001-02-22
US20020082301A1 (en) 2002-06-27
US7087647B2 (en) 2006-08-08
NO20020772L (no) 2002-02-15
IL147794A0 (en) 2002-08-14
PT1253918E (pt) 2008-11-20
AU6642400A (en) 2001-03-13
JP2003527320A (ja) 2003-09-16
MXPA02001587A (es) 2003-07-21
IL147794A (en) 2007-07-04
CN100450475C (zh) 2009-01-14
WO2001012170A3 (en) 2002-09-06
CA2689735A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
DK1253918T3 (da) Præparater der omfatter modafinil til behandling af forstyrrelse af opmærksomhed og aktivitet ("Attention Deficit Hyperactivity Disorder" ADHD))
DK0705099T3 (da) Anvendelse af modafinil til behandling af søvnapnø og åndedrætslidelser af central oprindelse
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE69034149D1 (de) Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen
DK0751939T5 (da) Naphthylamider som centralnervesystemmidler
ATE307592T1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
UA70925C2 (uk) Спосіб лікування естрогенстимульованого раку
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
DK0839143T3 (da) Tetralinforbindelser med MDR-aktivitet
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
NO20041166L (no) Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
DK89697A (da) Anvendelse af melatonin til behandling af patienter, der lider af medikamentafhængighed
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
MY126607A (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
DK0774961T3 (da) Anvendelse af selegilin til behandling af epileptiske lidelser
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE285778T1 (de) Topische verabreichung von bestimmten azapriranen zur vorbeugung oder behandlung von hautzuständen, die mit hautzellhyperproliferation und/oder immunologisch vermittelten krankheiten verbunden sind
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
DE59808106D1 (de) Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe
ATE269714T1 (de) Tcf-ii für vorbeugung und/oder behandlung von strahlungsinduzierter störungen
NO20034741D0 (no) Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser
Drozd P140 Psychopathology and psychotherapies
NIKOLOVA THE RIGHTS OF THE HANDICAPPED PERSONS IN CASE OF THE LOW FOR SOCIAL CARE
Fairweather et al. P. 1.042 Fluoxetine and dothiepin in depressed patients: A comparison of efficacy and effects on cognition and subjective sleep